| C27 | Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP | On-demand oral abstract session | PrEP |
| C27 | SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-Sero | On-demand oral abstract session | PrEP |
| C27 | Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019 ' June 2020 | On-demand oral abstract session | PrEP |
| C27 | Uptake of oral pre-exposure prophylaxis for HIV infection among men who have sex with men and transgender: lessons learned during the SARS-CoV-2 pandemic from the first PrEP project in Myanmar | On-demand oral abstract session | PrEP |
| C27 | HIV risk behaviors among retail pharmacy clients seeking sexual and reproductive health services in Kenya | On-demand oral abstract session | PrEP |
| C27 | STI incidence among participants in the HIV Pre-exposure Prophylaxis (PrEP) impact trial in England | On-demand oral abstract session | PrEP |
| C27 | Safety and pharmacokinetics of oral islatravir once monthly for HIV pre-exposure prophylaxis (PrEP): week 24 analysis of a phase 2a trial | Oral abstract session with live Q&A | PrEP |
| C27 | Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase | Oral abstract session with live Q&A | PrEP |
| C27 | Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US | Oral abstract session with live Q&A | PrEP |
| C27 | Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW | Oral abstract session with live Q&A | PrEP |